We are live on ! Find out more
SVCM

Saturn V Capital Management Portfolio holdings

AUM $552M
1-Year Est. Return 551.78%
This Fund
S&P 500
This Quarter Est. Return
-13.14%
1 Year Est. Return
+551.78%
3 Year Est. Return
+970.54%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$198M
AUM Growth
-$57.2M
Cap. Flow
-$15.2M
Cap. Flow %
-7.68%
Top 10 Hldgs %
77.38%
Holding
25
New
1
Increased
11
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$7.34M
2
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$5.47M
3
MRUS
Merus
MRUS
+$3.86M
4
XENE icon
Xenon Pharmaceuticals
XENE
+$3.46M
5
OCUL icon
Ocular Therapeutix
OCUL
+$3.13M

Top Sells

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$16.4M
2
CRGX
CARGO Therapeutics
CRGX
+$14.5M
3
ARGX icon
argenx
ARGX
+$3.72M
4
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$3.61M
5
KALV
KalVista Pharmaceuticals
KALV
+$3.08M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.3B
$31.1M 15.67%
199,264
+287
+0.1% +$41K
IRON icon
2
Disc Medicine
IRON
$2.78B
$25.7M 12.98%
518,177
+8,771
+2% +$488K
CGON icon
3
CG Oncology
CGON
$6.3B
$14.1M 7.14%
577,696
-15,566
-3% -$438K
XENE icon
4
Xenon Pharmaceuticals
XENE
$6.22B
$13.9M 7%
413,711
+91,241
+28% +$3.46M
MRUS
5
DELISTED
Merus
MRUS
$13.6M 6.87%
323,211
+88,574
+38% +$3.86M
MLTX icon
6
MoonLake Immunotherapeutics
MLTX
$1.63B
$13.4M 6.78%
343,849
-2,262
-0.7% -$97.5K
SNDX icon
7
Syndax Pharmaceuticals
SNDX
$1.74B
$12.8M 6.46%
1,041,280
+52,752
+5% +$744K
CELC icon
8
Celcuity
CELC
$3.88B
$11.1M 5.58%
1,093,677
+29,894
+3% +$338K
COGT icon
9
Cogent Biosciences
COGT
$6.68B
$8.87M 4.47%
1,480,020
-18,405
-1% -$144K
PCVX icon
10
Vaxcyte
PCVX
$7.91B
$8.77M 4.43%
232,295
+28,010
+14% +$2.24M
AMLX icon
11
Amylyx Pharmaceuticals
AMLX
$2.14B
$8.59M 4.33%
2,426,436
+1,537,363
+173% +$5.47M
ARGX icon
12
argenx
ARGX
$54.7B
$8.2M 4.14%
13,862
-5,892
-30% -$3.72M
CNTA
13
DELISTED
Centessa Pharmaceuticals
CNTA
$6.45M 3.26%
+448,692
New +$7.34M
OCUL icon
14
Ocular Therapeutix
OCUL
$1.82B
$4.38M 2.21%
598,191
+406,735
+212% +$3.13M
CTNM
15
Contineum Therapeutics
CTNM
$496M
$3.92M 1.98%
560,979
-12,043
-2% -$110K
ABVX
16
Abivax
ABVX
$10.6B
$3.46M 1.74%
552,926
-100,145
-15% -$678K
KALV
17
DELISTED
KalVista Pharmaceuticals
KALV
$2.94M 1.49%
255,060
-301,429
-54% -$3.08M
NAMS icon
18
NewAmsterdam Pharma
NAMS
$3.34B
$2.38M 1.2%
116,353
+16,353
+16% +$364K
SLN
19
Silence Therapeutics
SLN
$520M
$2.07M 1.04%
732,463
+337,439
+85% +$1.65M
CRNX icon
20
Crinetics Pharmaceuticals
CRNX
$8.89B
$1.98M 1%
59,017
-108
-0.2% -$4.03K
INZY
21
DELISTED
Inozyme Pharma
INZY
$454K 0.23%
499,254
-875,328
-64% -$1.21M
CRGX
22
DELISTED
CARGO Therapeutics
CRGX
– –
-1,007,677
Closed -$14.5M
CYTK icon
23
Cytokinetics
CYTK
$10.8B
– –
-348,364
Closed -$16.4M
IRWD icon
24
Ironwood Pharmaceuticals
IRWD
$632M
– –
-814,533
Closed -$3.61M
MBX
25
MBX Biosciences
MBX
$2.83B
– –
-18,000
Closed -$332K

Similar funds

LF
Longbow Finance Lutry, Switzerland $552M AUM 40.08% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $552M AUM 26% 1-Year Est. Return
DCM
Davidson Capital Management Corpus Christi, Texas $552M AUM 22.73% 1-Year Est. Return
TC
Triata Capital Hong Kong $552M AUM 2.89% 1-Year Est. Return
BT
Brandywine Trust Hockessin, Delaware $552M AUM 5.23% 1-Year Est. Return
CA
Crossingbridge Advisors Pleasantville, New York $553M AUM 1.29% 1-Year Est. Return
IQI
Integrated Quantitative Investments Bellevue, Washington $551M AUM 45.27% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $553M AUM 26.47% 1-Year Est. Return

Saturn V Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Saturn V Capital Management held 25 positions worth $198M, down 22% from $255M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Saturn V Capital Management withdrew a net $15.2M in Q1 2025, closing 4 positions and reducing 9 holdings. Its most notable exit was Cytokinetics, an estimated $16.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Saturn V Capital Management opened a new position in Centessa Pharmaceuticals worth $6.45M.

  • Saturn V Capital Management's largest Q1 2025 buy was Centessa Pharmaceuticals: 448,692 shares worth $6.45M.
  • Saturn V Capital Management added most to Amylyx Pharmaceuticals in Q1 2025, an estimated $5.47M increase.
  • Saturn V Capital Management's biggest Q1 2025 reduction was argenx, cutting an estimated $3.72M.
  • Saturn V Capital Management fully exited Cytokinetics in Q1 2025, selling an estimated $16.4M.
  • Saturn V Capital Management's ten largest holdings make up 77% of its $198M portfolio in Q1 2025.
  • Saturn V Capital Management opened 1 new position and closed 4 in Q1 2025.
  • Saturn V Capital Management's portfolio value fell 22% quarter-over-quarter to $198M.

Based on Saturn V Capital Management's 13F filing for Q1 2025, filed 15 May 2025.